DIMETHYLCURCUMIN

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H24O6
Molecular Weight	396.4331
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(OC)C=C(C=C1)\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(OC)C=C2

InChI

InChIKey=HMJSBVCDPKODEX-NXZHAISVSA-N

InChI=1S/C23H24O6/c1-26-20-11-7-16(13-22(20)28-3)5-9-18(24)15-19(25)10-6-17-8-12-21(27-2)23(14-17)29-4/h5-14H,15H2,1-4H3/b9-5+,10-6+

HIDE SMILES / InChI

Molecular Formula	C23H24O6
Molecular Weight	396.4331
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	2
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23219429 | https://clinicaltrials.gov/ct2/show/NCT01289574 | https://www.ncbi.nlm.nih.gov/pubmed/27564257

ASC-J9, also known dimethylcurcumin, is an androgen receptor (AR) degradation enhancer, it suppresses AR function via selective interruption between androgen receptors (ARs) and its selective co-activators (ARA55 or ARA70). This drug was successfully passed phase II clinical trial for topical application to treat the facial acne. In addition, ASC-J9 participated in the preclinical experiments to suppress prostatitis by altering the autoimmune response induced by CD4 T cell recruitment. In combination with sorafenib was shown, that ASC-J9 suppressed the hepatocellular carcinoma (HCC) progression via altering the pSTAT3-CCL2/Bcl2 signals.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
regulation of androgen receptor activity 1 Target ID: GO:2000823 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23219429	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Acne 100 Sources: https://clinicaltrials.gov/ct2/show/NCT01289574	Primary	Phase II 1147	Unknown Approved Use Unknown
Hepatocellular carcinoma 83 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27668844	Primary	Preclinical	Unknown Approved Use Unknown
Prostatitis 25 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27564257	Primary	Preclinical	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P001S49	https://www.1pchem.com/search?query=1P001S49
Biopurify Phytochemicals	BP3128	https://www.phytopurify.com/search.do?a=s&searchtype=3&psize=10&q=BP3128&searchhtmp=simplesearch&t=1
BLD Pharm	BD767515	http://www.bldpharm.com/search/Search.html?keyword=BD767515
Cayman Chemical	10009986	http://www.caymanchem.com/app/template/Product.vm/catalog/10009986
eMolecules	30497384	https://orderbb.emolecules.com/search/#?query=30497384
eMolecules	44849895	https://orderbb.emolecules.com/search/#?query=44849895
Lab Network	LN01315361	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01315361
mcule	MCULE-3455891789	https://mcule.com/MCULE-3455891789/
MolPort	MolPort-009-019-556	https://www.molport.com/shop/molecule-link/MolPort-009-019-556
ShangHai Biochempartner	BCP17149	http://www.biochempartner.com/search_BCP17149
Toronto Research Chemicals	C838523	https://www.trc-canada.com/product-detail/?CatNum=C838523

PubMed

Title	Date	PubMed
Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.	2017-11	28528814
Targeting androgen receptor with ASC-J9 attenuates cardiac injury and dysfunction in experimental autoimmune myocarditis by reducing M1-like macrophage.	2017-04-15	28246012
Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.	2017-02-01	27668844
Correction: ASC-J9 Suppresses Renal Cell Carcinoma Progression by Targeting an Androgen Receptor-Dependent HIF2a/VEGF Signaling Pathway.	2016-10-01	27698191
Determination of androgen receptor degradation enhancer ASC-J9(®) in mouse sera and organs with liquid chromatography tandem mass spectrometry.	2014-01	24042123
New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.	2013-02	23219429

Sample Use Guides

In Vivo Use Guide

Acne: cream for twice daily topical application to the face

Route of Administration: Topical

In Vitro Use Guide

It was screened natural products and their derivatives to determine which ones could interrupt the interaction between AR-ARA55 in prostate stromal WPMY-1 cells and/or AR-ARA70 in luminal epithelial LNCaP cells. It was found, that 5uM ASC-J9 could promote the dissociation of AR-ARA55 complex in WPMY-1 cells by using the Co-IP assay and the mammalian two-hybrid assay. A similar observation was seen in AR-ARA70 complex in LNCaP cells with ASC-J9 treatment. It was found that ASC-J9 had less effect in interrupting the interaction between AR and AR coregulator SRC-1 in LNCaP cells, suggesting that ASC-J9 could differentially interrupt the interactions between AR and selective AR coregulators.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:00:41 GMT 2025` Edited by `admin` on `Mon Mar 31 23:00:41 GMT 2025`
Record UNII	D60XLY608D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ASCJ-9

Preferred Name

English

DIMETHYLCURCUMIN

Systematic Name

English

CHC-004

Code

English

1,6-HEPTADIENE-3,5-DIONE, 1,7-BIS(3,4-DIMETHOXYPHENYL)-, (1E,6E)-

Systematic Name

English

GO-Y-025

Code

English

Code System Code Type Description

DRUG BANK

DB06133